Access Denied
IMPORTANT! If you’re a store owner, please make sure you have Customer accounts enabled in your Store Admin, as you have customer based locks set up with EasyLockdown app. Enable Customer Accounts
DISCOVER
Innovation in Automatic Function Testing
SUDOSCAN® is a quick and non-invasive test to assess peripheral autonimic neurophathy.
SUDOSCAN® evaluates the function of sweat glands innervated by the peripheral system. By testing sweat function, SUDOSCAN® allows physicians to detect and follow up neuropathy to better personalize and monitor patient treatment plans.
FAST
- No patient preparation
- Results in 3 minutes
- Easy-to-read critical data points to help
- Physicians reach a diagnosis
ACCURATE
- Highly reproducible
- Quantitative results
- Backed by evidence-based research
- Independent from environmental conditions
The Science
SUDOSCAN® is a test that provides an accurate evaluation of sweat gland function. The test focuses on small nerve fibers that innervate the sweat glands. The degeneration of small nerve fibers reduces sweat gland innervation and impairs sudomotor function.
SUDOSCAN® measures the ability of the sweat glands to release chloride ions in response to an electrical stimulus on the palms of the hands and soles of the feet, areas with the highest sweat gland density.
SUDOSCAN® Technology
Learn more about SUDOSCAN®
SUDOSCAN®
An Innovative Technology
SUDOSCAN® is a patented technology that evaluates sweat gland function, which is controlled by small nerves like some of those involved in pain sensation.
The polarity of the stainless steel sensor plates is swapped during a scan to record individual right and left side conductance values. The amount of observed asymmetry can sometimes help the physician in determining a diagnosis.
SUDOSCAN® and type 2 diabetes
Small nerve fibers are the very first targets of diabetes. For a substantial number of patients, irreversible tissue damage (peripheral vascular disease, nephropathy, retinopathy, neuropathy) have already set in at the time of diagnosis [1]. 60-70% of patients with diabetes have neuropathies [2].
Early identification of these complications, which may be asymptomatic in up to 50% of diabetic patients, has the potential to reduce or delay their complications with timely preventative treatment.
The American Diabetes Association (ADA) mandates that all patients with diabetes be screened annually for peripheral and autonomic neuropathy.
Simply Put: Less Invasive and More Reliable.
The use of skin biopsy (IENFD) is an accepted diagnostic measure of small fiber neuropathy, but it has certain limitations: invasiveness, risk of infection, poor healing process for diabetic patients, and a limited number of labs that can process the samples. [3]
Nerve conduction studies (NCS) are the gold standard for the diagnosis of peripheral neuropathy, but can only assess large myelinated fibers. Therefore, for symptomatic patients with normal NCS, small nerve fiber evaluation is recommended. [4]
SUDOSCAN’s diagnostic performance (ESC) is comparable to ENFD/SGNFD and QSART in detecting Neuropathy.
Peter Novak, Autonomic Laboratory, Department of Neurology, Brigham and Women’s Faulkner Hospital, Harvard Medical School, Boston, MA, USA. Read full article here
SUDOSCAN® Technology Articles
Diabetes Tech and Ther.
Vinik AI, Smith AG, Singleton JR, Callaghan B, Freedman B, Tuomilehto J, Bordier L, Bauduceau B, Roche F.https://pubmed.ncbi.nlm.nih.gov
Electrochemical Acta 2014;140(10):37-41
Calmet A, Khalfallah K, Ayoub H, Lair V, Griveau S, Brunswick P, Bedioui F, Cassir M.https://www.sciencedirect.com/
Sensor Letters journal 2011;9:2147-49
Ayoub H, Lair V, Griveau S, Brunswick P, Bedioui F, Cassir M.https://www.ingentaconnect.com/
IEEE sensors Journal 2010 :12(3) :456-63
Khalfallah K, Ayoub H, Calvet JH, Neveu X, Brunswick P, Griveau S, Lair V, Cassir M, Bedioui F.https://ieeexplore.ieee.org/
Invalid password
Enter
